glp 1 resistencia a la insulina GLP-1: El Puente entre Glucosa, Saciedad y Peso Corporal Existe un espacio para los

Trial-Reported Endpoints by Phase Trial Lancet 2021 Phase 2 Duration 26 weeks Population Overweight/obese, no T2D (n=706) Mean Weight Loss 10.8% at 4.5 mg vs 3.0% placebo Trial Lancet 2023 Phase 2 Duration 32 weeks Population T2D + obesity (n=92) Mean Weight Loss 8.1% cagrilintide alone

PET has historically been widely used for drug occupancy studies in the brain specifically 15

It has also been shown that people without Type 2 diabetes can benefit from the weight loss side effect

The milligram numbers are not directly comparable because each peptide has different potency per milligram at its target receptors

PMID 26251262